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Abstract: MicroRNA regulation is crucial for gene expression and cell functions. It has been linked to
tumorigenesis, development and metastasis in colorectal cancer (CRC). Recently, the let-7 family has
been identified as a tumor suppressor in different types of cancers. However, the function of the let-7
family in CRC metastasis has not been fully investigated. Here, we focused on analyzing the role of
let-7g in CRC. The Cancer Genome Atlas (TCGA) genomic datasets of CRC and detailed data from
a Taiwanese CRC cohort were applied to study the expression pattern of let-7g. In addition, in vitro
as well as in vivo studies have been performed to uncover the effects of let-7g on CRC. We found that
the expression of let-7g was significantly lower in CRC specimens. Our results further supported the
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inhibitory effects of let-7g on CRC cell migration, invasion and extracellular calcium influx through
store-operated calcium channels. We report a critical role for let-7g in the pathogenesis of CRC and
suggest let-7g as a potential therapeutic target for CRC treatment.
Keywords: colorectal cancer; microRNA; let-7g; the cancer genome atlas (TCGA), store-operated
calcium (SOC)
1. Introduction
Micro (mi)RNAs are short, single-stranded non-coding RNAs which function as
post-transcriptional regulators of gene expression and are involved in fundamental biological
processes. First identified from developmental timing in the model animal Caenorhabditis elegans,
miRNA is well-known for conserved properties among different species [1]. Recently, many studies
have been published showing that miRNAs are involved in critical human diseases, including
cancer [2–4]. miRNAs suppress gene expression through imperfect base-pairing with a complementary
sequence in the 3′-untranslated region (UTR) of target messenger (m)RNAs and then inhibit target
protein synthesis by preventing translation or inducing mRNA degradation [5,6]. The biological
roles of miRNAs are as regulators of several cellular events, such as proliferation, differentiation
and apoptosis, which are associated with cancer progression [6,7]. For instance, miR-21 mediates
the post-transcriptional modification of a tumor suppressor, thereby stimulating colorectal cancer
(CRC) invasion, intravasation and metastasis [8]. Ma et al. stated that miR-9 causes E-cadherin
downregulation and activates β-catenin signaling to enhance the level of vascular endothelial growth
factor (VEGF), which in turn promotes breast tumor angiogenesis [9].
The let-7 family, one of the first discovered miRNAs, functions as key regulators in development
and cancer [10,11]. During C. elegans development, let-7 is present in the larval to adult stages and
causes seam cells to stop dividing and differentiate [12]. In let-7 mutant nematodes, seam cells fail to
exit the cell cycle, leading to continuous seam cell division and the death of the worms, so the name
lethal-7 was given to it after this discovery [11]. There are 13 kinds of let-7 in humans, among which
let-7g has been proven to be tightly associated with hepatocellular carcinoma (HCC), non-small cell
lung tumors, breast cancer and CRC [13–18]. Previous studies observed the reduction of let-7g in tumor
tissues of metastatic HCC patients. Overexpression of let-7g suppressed HCC cell migration, invasion
and proliferation via regulating type I collagen α2 (COL1A2), c-Myc and p16 [15,19]. Other studies
demonstrated that expression of let-7g was significantly reduced in tumor tissues of breast cancer
patients and even lower in those with lymph node metastasis [16,20]. These studies further unveiled
inhibitory effects of let-7g on breast cancer cell metastasis and proposed that estrogen and epidermal
growth factor (EGF) promote breast tumor cell migration and invasion by suppression of let-7g through
44/42 mitogen-activated protein kinase (MAPK) signaling activation.
CRC is the third leading cause of cancer deaths around the world [21]. Around 25% of CRC
patients suffer from metastatic events, and yet the mechanism of CRC metastasis has not been fully
explored due to complex environmental and genomic factors [22–24]. The study of let-7 miRNAs could
be a possible route to understanding the mechanism of tumor progression and metastasis. Nakajima et
al. previously unveiled a significant increase of let-7g level in tumor tissues of CRC patients and its
association with the poor chemo-response and progressive disease of CRC [13]. Wang et al. further
observed that the expression level of let-7g was significantly higher in circulating blood samples from
CRC patients than in those from healthy individuals [25]. Although let-7g was found to be involved
in tumorigenesis of CRC by these studies, whether the functional effects of let-7g have special roles
in colon cancer progression and metastasis needs further investigation based on a systematic and
comprehensive study.
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To address the questions, applied integrated bioinformatics approaches, functional validation
using different CRC samples cohort sets, as well as in vitro and in vivo experiments were conducted.
We identified let-7g-associated clinical features, transcriptomic profiles and biological pathways in
a large CRC cohort from The Cancer Genome Atlas (TCGA) database. Reduced let-7g levels in tumor
tissues compared to adjacent normal tissues was observed in a Taiwanese population CRC cohort.
Functional studies based on in vitro and in vivo approaches further revealed suppressive effects of
let-7g on CRC cell migration, invasion and store-operated calcium (SOC) influx. In summary, our results
provided clinicopathological significance for let-7g and in CRC progression, and implicated a role for
store-operated Ca2+ entry in let-7g-mediated CRC metastasis. let-7g could be of great pharmaceutical
interest for anti-cancer drug discovery.
2. Results
2.1. Correlation between let-7g Expression and Clinical Profiles in CRC Patients
TCGA CRC samples with available let-7g RNA-sequencing data were categorized into let-7g
high-expression and let-7g low-expression groups based on two criteria: quartiles (n = 165) and
quintiles (n = 133, Figure 1A, upper panel). Based on the quartile categorization criteria, we conducted
correlation analysis between dichotomized let-7g expression statuses and clinical profiles (Table S1).
Results showed a correlation between let-7g expression and lymphatic invasion (p = 0.027, adjusted
p = 0.07). Notably, the expression status of let-7g showed a negative correlation with the lymphatic
invasion status, with 50 of 92 (54.3%) patients without lymphatic invasion belonging to the let-7g
overexpression group, while 17 of 49 (34.7%) patients with lymphatic invasion belonging to the let-7g
overexpression group. In contrast, although trends of a negative correlation of the let-7g expression
status with lymph node metastasis, distant metastasis, disease stage and vascular invasion were
observed, none of them reached statistical significance (p < 0.05). These results imply a tumor
suppressive role of let-7g in CRC.
Figure 1. Cont.
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Figure 1. Transcriptomic profiles and functional annotations correlated with let-7g overexpression.
(A) Schematic showing patient categorization of The Cancer Genome Atlas (TCGA) colorectal cancer
(CRC) samples. CRC samples were stratified into two groups (overexpression (high) and low-expression
(low)) based on the expression value (−log2(RPM)) of let-7g. Two categorization criteria (quartiles
and quintiles) were applied to assess the robustness of the results and were used for a downstream
exploratory analysis (upper panel). Numbers of significantly upregulated and downregulated
differentially expressed genes (DEGs) based on quartile and quintile categorization are shown (lower
panel). (B) Heatmap of the top 200 most variant DEGs based on quartile categorization in the RNA
sequencing profile. Each column represents CRC samples, and each row represents genes. Two-way
hierarchical clustering was performed, and the information of the let-7g expression status and the
CRC location were mapped. (C) Non-negative matrix factorization was performed on the top 200
most variant differentially expressed genes (DEGs) based on quartile categorization. Heatmaps of the
metagene matrix constructed with 20 genes were obtained from a factorization rank of 3. (D) Of these,
18 genes which were positively correlated to clusters 1 and 2 were used to assess the over-represented
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology (GO) biological
process (BP) terms.
2.2. Let-7g-Associated Transcriptomic Profiles Reveal Three CRC Subpopulations
Eighty-three let-7g high-expression and 82 let-7g low-expression samples based on quartile
categorization and 67 let-7g high-expression and 66 let-7g low-expression samples based on quintile
categorization were subjected to an RNA-sequencing profile analysis to identify differentially expressed
genes (DEGs) associated with the let-7g expression status. We used a moderated t-test to identify
significant DEGs in each categorization. In total, 3222 (quartile) or 2673 (quintile) upregulated DEGs
and 2023 (quartile) or 1503 (quintile) downregulated DEGs were identified and fulfilled the Benjamini
and Hochberg (BH)-adjusted p-value criteria of <0.05 among the let-7g high-expression group and
let-7g low-expression group, respectively (Figure 1A, lower panel). We noted that the number of
identified DEGs in the quintile categorization was smaller than that of the quartile categorization;
this was because the quintile categorization can be considered as a more-stringent criteria which
included a smaller number of samples.
To explore the aggregative effects of CRC samples based on let-7g-associated profiles, we further
conducted an unsupervised hierarchical clustering analysis based on the identified DEGs. A heatmap
of the top 200 most significant DEGs based on the quartile categorization was visualized (Figure 1B),
and a three-group gathering configuration was observed, revealing three highly clustered sample-based
within-group expression patterns. To validate this exploratory result, we further conducted the same
clustering analysis based on the top 100 and 300 DEGs in the quartile categorization, and results
suggested that the three-group gathering configuration was also distinguishable (Figure S1A).
The analysis focused on the top 100, 200 and 300 DEGs based on the quintile categorization also
showed the same three-group gathering pattern (Figure S1B). Based on these results, three sample
groups were identified: a group enriched in let-7g overexpression patients, which was correlated with
downregulation of most of the top DEGs (let-7g-enriched); a group enriched in let-7g low-expression
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patients, which was correlated with upregulation of most of the top DEGs (let-7g-less); and a group
composed of similar proportions of patients of let-7g overexpression and low-expression, which showed
no significant correlation with the top DEGs (let-7g-unrelated).
To validate the robustness of the clusters identified, non-negative matrix factorization (NMF) was
carried out against the top 100, 200 and 300 DEGs in both the quartile and quintile categorization.
We adopted the Brunet algorithm to perform the NMF analysis on the factorization rank between
2 and 6 in 200 runs. As expected, all results showed that the optimal number of clusters was three,
which showed the strongest consensus signature (Figures S2 and S3).
Notably, when CRC samples were stratified into three groups based on NMF, the let-7g-less group
(cluster 1) had a significantly higher incidence of advanced-stage tumors (FDR adjusted p = 0.038) and
lymphatic invasion (FDR adjusted p = 0.044) compared to the let-7g-enriched group (cluster 2) and
let-7g-unrelated group (cluster 3, Table 1).
Table 1. Correlations between clinic pathological features and non-negative matrix factorization (NMF)
clusters (quantile categorization) for colorectal cancer patients.
Characteristics










T1 + T2 28 2 (7.1) 16 (57.1) 10 (35.8) 0.015 * 0.019 * 0.038 *
T3 + T4 136 38 (27.9) 45 (33.1) 53 (39.0)
Lymphatic Invasion
No 92 17 (18.5) 37 (40.2) 38 (41.3) 0.026 * 0.044 * 0.044 *
Yes 49 17 (34.7) 13 (26.5) 19 (38.8)
a Adjusted the effects of diagnosed age, gender and location (colon and rectum); b Adjusted the effects of diagnosed
age, gender and location (colon and rectum), followed by Benjamini-Hochberg multiple correction; * A p-value of
<0.05 was considered statistically significant. FDR: false discovery rate.
2.3. Targets of let-7g were Significantly Enriched in let-7g-Associated Profiles
To further assess the biological significance of the characterized let-7g-associated profiles, we first
queried let-7g targets using the TarBase (v7.0) database. Then, we tested whether genes in the target
list showed enrichment for association (p-value) and magnitude (fold-change) signals. Intriguingly,
the let-7g targets showed highly significant enrichment for association signal (p = 9.99 × 10−5) and
magnitude signal (p = 3 × 10−4) in comparison with non-target genes based on quartile categorization.
Similar results (association signal (p = 9.99 × 10−5) and magnitude signal (p = 4.1 × 10−4)) were also
observed based on quintile categorization (Figure S4).
2.4. Prospecting let-7g-Associated Biological Features in CRC Patients
To identify the underlying biological signatures correlated with let-7g expression, we next
extracted the most important DEGs from let-7g-associated profiles and conducted the
over-representation analysis for these genes. We first extracted 20 DEGs as selected features for
metagenes specific to three let-7g-associated CRC subtypes identified as previously described based on
a NMF-based feature extraction approach (Figure 1C). We further selected 18 metagene-specific DEGs
from the let-7g-less group (cluster 1) and the let-7g-enriched group (cluster 2) as the most important
let-7g-associated DEGs for investigating relevant biological features (Figure 1D). Two significant
over-represented Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were identified:
extracellular matrix (ECM)-receptor interaction and focal adhesion, which are known to be correlated
with tumor aggressiveness and metastasis. In addition, based on the results of the gene ontology
(GO) biological process (BP) analysis, we observed several over-represented terms related to calcium
ion signaling and cell motility (Figure 1D), including positive regulation of the cytosolic calcium ion
concentration (GO:0007204), cellular calcium ion homeostasis (GO:0006874), positive regulation of
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cell motility (GO:2000147), and positive regulation of cell migration (GO:0030335). Other significantly
over-represented GO BP terms are shown in Table S2.
To gain biological insights into the transcriptomic regulatory role of let-7g, we conducted
a signaling pathway impact analysis (SPIA) based on quartile categorization criteria. Significant
pathways (p = 2 × 10−6) are listed in Table S3. The focal adhesion pathway (Figure S5), calcium
signaling pathway (Figure S6), and ECM-receptor interaction pathway (Figure S7), which were
consistent with the results of over-representation analysis (ORA), showed significant negative
perturbation evidence. In addition, cytokine- and chemokine-related pathways were also significantly
negatively perturbed (Figures S8 and 9). Specifically, SPIA results revealed a significant negative
perturbation of pathways in cancer (Figure S10), suggesting a comprehensive negative impact of let-7g
overexpression on cancers.
2.5. Reduced let-7g in CRC Specimens
To further investigate the role of let-7g in CRC, we quantified the level of let-7g in 20 CRC patients.
Real-time qPCR data showed that the level of let-7g was significantly lower in cancer specimens in
comparison with that of adjacent benign tissues (Wilcoxon rank sum p = 1.04 × 10−4). The expression
ratio of let-7g in the CRC cohort was calculated by tumor versus normal tissues. As shown in Figure 2B,
16 of 20 (80%) CRC patients showed decreased expression of let-7g in tumor tissues compared to
paired adjacent normal tissues. In addition, we also investigated the clinicopathological role of let-7g
in a Taiwanese CRC cohort. However, none of the clinical parameters showed a significant correlation
with let-7g expression levels (Table S4).
Figure 2. Expression of let-7g in a cohort of colorectal cancer (CRC) patients. (A) Whisker boxplot
shows let-7g mRNA values of tumor tissues and paired adjacent normal tissues in 20 CRC samples.
(B) Bar plot shows the relative expression ratio between let-7g from tumor versus paired normal tissues
around the cancer tissue of each CRC patient.
2.6. Let-7g Inhibits CRC Cell Migration in Vitro
We tested whether let-7g affects the migration of colon cancer cells. As shown in Figure 3A,
EGF-induced cell migration of Caco-2 cells was diminished by let-7g in a wound-healing assay.
Additionally, we also observed an inhibitory effect of let-7g on DLD-1 cell migration in both the
wound-healing assay and biosensor experiment for migration (Figure 3B–D). Accordingly, our results
showed that let-7g was capable of inhibiting CRC cell migration.
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Figure 3. Effect of let-7g on cell migration in colorectal cancer cells. (A,B) A cell-free gap was generated
by seeding a miRNA negative control and let-7g-transfected cells inside a culture insert to perform
a wound-healing assay. The cell migration of Caco-2 (magnification, ×10) and DLD-1 (magnification,
×20) cells with and without epidermal growth factor (EGF) treatment was assessed by imaging at 0- and
24-h time points. (C) The real-time cell migration of the miRNA negative control and let-7g-transfected
DLD-1 cells was analyzed by an x’Celligence Biosensor System. (D) The real-time DLD-1 cell migration
after 72 h was quantified. **, statistically significant at a p-value of <0.01.
2.7. Both let-7g and the Store-Operated Calcium (SOC) Channel Blocker SKF96365 Inhibit CRC Cell Motility
in Vitro
A previous study demonstrated that SOC is critical during CRC progression and metastasis
and indicated suppressive effects of SOC inhibitors on CRC migration [26]. To further investigate
whether the mechanism by which let-7g inhibits CRC migration is correlated with the underlying
SOC inhibition, we determined and compared the influences of let-7g and SKF96365, a SOC inhibitor,
on cell motility. Results revealed that both let-7g and SKF96365 inhibited the migration and invasion of
DLD-1 cells (Figure 4A). The numbers of migrating and invasive cells significantly decreased with
let-7g overexpression and SKF96365 treatment (Figure 4B,C). These results suggest that let-7g and the
SOC inhibitor had similar inhibitory effects on CRC cell migration and invasion. Based on these results,
we further examined the influences of let-7g and the SOC inhibitor on the epithelial-mesenchymal
transition (EMT), which was indicated to be involved in the progression and metastasis of CRC
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cells [27,28]. Our results showed that both let-7g and SKF96365 increased E-cadherin, an epithelial
marker and decreased mesenchymal markers including N-cadherin and vimentin in DLD-1 cells,
reflecting a reduced migratory ability (Figure 4D,E). Additionally, expression of phospho-Akt was
found to be inhibited by let-7g and SKF96365, suggesting suppressive influences of let-7g and the SOC
blocker on tumor progression, including cell proliferation and metastasis (Figure 4D,E). Our findings
indicated that both let-7g and the SOC inhibitor can block CRC cell motility.
Figure 4. Effect of let-7g and a store-operated calcium (SOC) channel inhibitor on the motility of
colorectal cancer cells. (A) DLD-1 cells transfected with a miRNA negative control and let-7g were
subjected to transwell migration and invasion assays. Cells were incubated with or without 10 µM
SKF96365 for 48 h and then analyzed by imaging. Scale bar: 100 µm. (B,C) DLD-1 cell migration
and invasion were quantified by calculating the number of stained cells. (D) Epithelial-mesenchymal
transition (EMT)-related protein levels in DLD-1 cells transfected with the miRNA negative control and
let-7g plus treatment with or without 10 µM SKF96365 were analyzed by Western blotting. The protein
expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was assessed as an internal
control. (E) Western blots of EMT-related protein expressions in DLD-1 cells were quantified. **,
statistically significant at a p-value of <0.01.
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2.8. Let-7g Attenuates SOC Influx in Vitro
Because both let-7g and the SOC inhibitor can block CRC cell motility, we further examined
the effects of let-7g on store-mediated calcium influx. Thapsigargin (TG), an inhibitor of
sarco/endoplasmic reticular Ca2+ ATPase (SERCA) pumps, was used to trigger classical SOC entry
(SOCE). The intracellular calcium imaging system was applied to detect TG-induced calcium release of
the ER in a calcium-free environment, following extracellular calcium influx through the SOC channel
by the addition of 2 mM calcium. Our data showed that TG-induced SOCE was significantly inhibited
by let-7g in Caco-2 cells (Figure 5).
Figure 5. Effect of let-7g on store-operated calcium (SOC) entry (SOCE) in colorectal cancer cells. (A) The
thapsigargin (TG)-induced Ca2+ influx via SOC in miRNA negative control and let-7g-transfected
Caco-2 cells. During calcium imaging, cells were treated with TG followed by 2 mM Ca2+ to induce
calcium release from the endoplasmic reticulum (ER) and to trigger extracellular influx, respectively.
(B) Ca2+ signals were quantified by calculating the black area beneath the Ca2+ curve caused by 2 mM
Ca2+. **, statistically significant at a p-value of <0.01.
2.9. Let-7g Inhibits Colorectal Tumor Growth in Vivo
To extend the findings from in vivo cell growth and motility in an animal model, tumor xenograft
models were used. In the study, mice were subcutaneously injected with Caco-2 cells to induce tumor
formation. Three days later, the mice were treated with either the miRNA negative control or let-7g
by an intraperitoneal injection of liposomes containing each miRNA twice a week. By continually
measuring the tumor volume during 17 days after the initial injection of CRC cells, we observed
an inhibitory influence of let-7g on CRC growth in mice (Figure 6C). After 17 days, smaller colorectal
tumors were also detected in mice treated with let-7g compared to those in mice with injection of the
miRNA negative control (Figure 6A). We further removed and measured tumor tissues from mice as
shown in Figure 6B. Our results revealed that both the tumor volume and weight of let-7g-treated mice
were significantly lower than those of mice treated with the microRNA negative control (Figure 6C,D).
Notably, the body weight of mice in the two groups showed no significant difference, suggesting no
adverse effects of let-7g on physiological functions of the mice (Figure 6E). Our finding from the in vivo
study demonstrated the strong suppressive effect of let-7g on CRC growth in a mouse model.
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Figure 6. Effect of let-7g on colorectal cancer cell growth in nude mice. (A) Nude mice orthotopically
transplanted with Caco-2 cells were treated with interval injections of a liposome-entrapped miRNA
negative control and let-7g. The orthotopic tumor size was imaged. (B) Orthotopic tumor tissues of
nude mice were surgically removed and imaged. (C) Orthotopic tumor sizes were measured at 3, 7,
14 and 17 days after tumor implantation. (D) The tumor weight of surgically removed tumor tissues
were measured. (E) The body weights of nude mice were measured. **, statistically significant at
a p-value of <0.01.
3. Discussion
This study combined the TCGA database and a Taiwanese CRC patient cohort study to test the
role of let-7g in CRC progression. In the TCGA database, a significant correlation between reduced
let-7g expression and lymphatic invasion was observed. A second cohort validation study in Kaohsiung
Medical University Hospital indicated that tissues from CRC patients had decreased levels of let-7g.
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In addition, functional studies revealed that let-7g inhibited CRC cell migration and invasion, vimentin
expression and store-operated calcium influx. Strikingly, results from the in vivo animal studies further
supported the protective effects of let-7g treatment on CRC progression. Hence, the expression level of
let-7g can influence physiological changes of CRC through calcium-dependent cell migration pathways.
Decreased expression levels of let-7g were reported in many types of cancer, including
hepatocellular carcinoma (HCC) [15,18], lung cancer [29], breast cancer [16] and gastric cancer [30].
In HCC, a lower level of let-7g was reported to be correlated with metastasis and poor overall
survival [15]. Breast cancer patients with lower let-7g expression also showed poor overall and
recurrence-free survival [16]. Similarly, down-regulation of let-7g was reported to correlate with a poor
prognosis in gastric cancer patients [30]. Previous studies considered the potential effects of let-7g on
cancer progression; here, our results from a TCGA data analysis (RNA-sequencing data) confirmed
the association between reduced let-7g expression and CRC progression. Additionally, a decreased
expression of let-7g in tumor tissues observed in our CRC cohort supported the crucial role of let-7g in
CRC development.
Several recent studies have been proposed for a role of let-7g in CRC progression. Nakajima et
al. reported a significant increase of let-7g in tumor tissues from 21 CRC patients [13]. In addition,
measuring the serum level of miRNAs indicated a significantly higher expression of let-7g in CRC
patients than that in healthy individuals [25]. However, another quantitative result revealed no
significant difference in let-7g expression between tumor and adjacent stromal tissues in 25 rectal
cancer patients [31]. It seems that the evidence cannot be reconciled with each other. However, in light
of the fact that there are so many examples that indicated store-operated calcium influx is a critical
pathway in cancer cell migration and proliferation [32–34], the functional results in the current study
indicate the inhibitory effects of let-7g in store-operated calcium entry. Consistent with this concept,
we observed low expression of let-7g in CRC tissues. Most studies addressing the roles of let-7g are
plagued with a number of uncertainties. We attribute this to the small clinical sample size, which may
lack of statistical power in the analysis. Further carefully designed studies are needed in order to
evaluate the influence of let-7g in carcinogenesis.
How let-7g results in CRC migration through calcium signals is unclear at present. Nevertheless,
results showed that let-7g can at least target, through attenuation of SOC signals, EMT pathways,
which involve the motility of cancer cells. Consistent with our findings, inhibitory functions of let-7g
on cell cancer cell motility were addressed. Overexpression of let-7g has been demonstrated to reduce
the proliferation, migration and invasion of HCC cells [35]. By inhibiting let-7g, breast cancer cell
migration and invasion were promoted via the downregulation of Grb2-associated binding protein 2
(GAB2) and fibronectin 1 (FN1) expressions that led to subsequent activation of MAPK pathways [16].
Indeed, our findings can be nicely incorporated into the model proposed by Qian and colleagues.
let-7g reduces the motility of cancer cells such that basal SOC might be insufficient to support FN1
expression and MAPK pathway activation.
Dysregulated SOC pathways were widely reported to promote cancer cell migration, invasion
and metastasis in various cancers [32–34]. Recent findings demonstrated that stromal interaction
molecule 1 (STIM1), an ER calcium sensor of SOCE, promoted the motility of CRC cells [26]. Notably,
STIM1 can be downregulated by miRNA-195 and miRNA-185, which results in abrogation of CRC
cell migration and invasion [26,36,37]. In our study, we identified the functional role of let-7g in SOC
mobilization. The mechanisms by which let-7g inhibited SOC signaling are as yet unclear. Previous
studies reported several genes (HMGA2, K-Ras, Bcl-xL, COL1A2, GAB2 and FN1) as potential targets of
let-7g. Although various genes were proposed to function in cancer cell motility pathways, there is,
as yet, no widely accepted candidate for let-7g in CRC cells. Additionally, it is not clear whether let-7g’s
mediation of calcium signals contributes equally to the activation of all of these genes or whether one
gene is preferentially involved [15,16,38–40].
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4. Materials and Methods
4.1. Data Acquisition and Patient Categorization of the TCGA CRC Cohort
We downloaded CRC (including colon adenocarcinoma (COAD) and rectum adenocarcinoma
(READ)) patients’ primary tumor data with available miRNA sequencing and RNA sequencing
(version 2) information using the TCGA Assembler [41]. The queried sequencing data were further
processed using the ProcessmiRNASeqData and ProcessRNASeqData functions as implemented in
the TCGA Assembler. We next extracted let-7g expression data (RPM), which were log-transformed,
and then queried the corresponding clinical profiles of CRC patients. The RNA sequencing expression
data of these patients were processed as follows: We considered a gene to be expressed if it was present
at a level of >0 in 80% of the samples, resulting in 16,387 transcripts. We further defined outliers as
those samples which were more than five standard deviations above the mean connectivity based on
a signed, weighted bi-weight mid-correlation using the WGCNA package and removed one outlier
sample, resulting in 327 samples [42]. Finally, expression values were normalized (rounding cutoff
equal to 1) using the sRAP package.
We categorized CRC samples based on let-7g expression values. In this study, we applied two
criteria (20% or 25%) to perform patient categorization. We defined CRC patients with a let-7g
expression value of larger than the upper quartile or quintile as the let-7g overexpression group;
and CRC patients with a let-7g expression value smaller than the lower quartile or quintile as the let-7g
low-expression group. Based on these criteria, 83 (upper quartile) and 82 (lower quartile) or 67 (upper
quintile) and 66 (lower quintile) samples were selected for downstream analysis.
4.2. Analysis of Clinical Demographics in TCGA CRC Samples
The 165 CRC patients selected based on quartile categorization were included to assess the
correlation between the let-7g expression status (let-7g high-expression or low-expression) and patients’
clinical profiles (including gender, diagnosed age, depth of invasion, lymph node metastasis, distant
metastasis, UICC staging, vascular invasion, lymphatic invasion and perineural invasion). A logistic
regression model under a binomial distribution was fitted for the association test. We also conducted
the same statistical model by adjusting for the effects of gender, age and tumor location (colon or
rectum). A p-value of <0.05 was considered statistically significant.
4.3. Analysis of Transcript Expression Profiles Based on Sample Categorization
Differentially expressed genes (DEGs) were identified by comparing let-7g high-expression and
low-expression based on the quartile or quintile categorization. We applied a moderated t-test to
identify DEGs [43]. We further defined significant DEGs as genes having a Benjamini and Hochberg
(BH)-adjusted p-value of <0.05. To visualize expression patterns of identified DEGs in CRC samples,
the top 100, 200 and 300 DEGs were extracted for a heatmap analysis. In addition, unsupervised
agglomerative hierarchical clustering was performed on these most variant DEGs with the following
parameters: distfun = “euclidean” and hclustfun = “average”. We further conducted a non-negative
matrix factorization (NMF) analysis using the NMF package [44]. In the NMF analysis, the stability of
consensus matrices under two to six factorization ranks was iteratively conducted using the Brunet
algorithm [45]. To evaluate the reproducibility of the clustering effect, the top 100, 200 and 300
DEGs under quartile and quintile categorization were all separately analyzed. Furthermore, cluster
signatures were extracted from the output results of the NMF analysis and further correlated with
patients’ clinical features.
4.4. DIANA-Annotated Targets Gene Set Enrichment Analysis
Target genes of let-7g were queried based on human orthologues using the online DIANA TOOLS
TarBase v7.0, an experimentally supported and manually curated miRNA target database [46]. A gene
set analysis was performed using a permutation test to compare p-values and multiples of change of
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1655 let-7g targets and the remaining genes. The p-values were log10-transformed and the absolute value
of the multiple of changes underwent a log10 transformation so that larger values represented higher
correlations (for the p-value) or larger changes (for multiples of change) across the let-7g overexpression
and low-expression groups. We generated a null distribution by 10,000 random permutations of the
gene labels and calculated the gene set enrichment score (ES) based on the Kolmogorov–Smirnov
statistic. Then, we scaled the ES by subtracting the mean and dividing by the standard deviation of the
permutated ES to obtain a normalized ES (NES; i.e., the Z-score). Finally, significant p-values were
calculated from the resulting Z-scores.
4.5. Gene Ontology (GO) Enrichment and Pathway Analysis of DEGs in CRC Samples
Following DEG identification, gene set analysis were performed. We first extracted a smaller
set of DEGs as the most important features for the metagene, which were generated from the
clustering of most variant DEGs based on NMF analysis and corresponded to cluster signatures
as let-7g-associated CRC subpopulations, by using a default feature extraction function implemented
in the NMF package [44,47]. Based on the result of feature extraction, parts of features corresponding
to specific cluster signatures were further selected for capturing let-7g-associated biological features.
We conducted a GO biological process (BP) term, and Kyoto Encyclopedia of Genes and Genomes
(KEGG) over-representation analysis (ORA) was carried out using the GOstats package to identify
enriched BP terms and KEGG pathways [48]. We selected a p-value cutoff of 0.05 in the ORA. We also
carried out signaling pathway impact analysis (SPIA) using the SPIA package to identify aberrant
KEGG pathways between the let-7g overexpression and low-expression groups [49]. Perturbation
p-values were calculated using 20,000 bootstrap iterations. Finally, the pathways that had p-values of
<2 × 10−6 were considered as significantly perturbed. The KEGG pathways were visualized using the
Pathview package [50].
4.6. Patient Recruitment and Sample Preparation
In total, 20 patients diagnosed with CRC were enrolled at Kaohsiung Medical University
Hospital. The study was conducted with approval from the institutional review board of Kaohsiung
Medical University, Taiwan (KMUHIRB-2012-03-02 (II)). All patients were provided with informed
consent for the study prior to data and sample collection. Both tumor and adjacent normal tissues
were surgically collected from CRC patients and homogenized in TRIzol reagent (Thermo Fisher
Scientific, Waltham, MA, USA). Total RNAs were then extracted from homogeneous tissue samples
following the manufacturer’s instructions and applied to a polymerase chain reaction (PCR) for a gene
expression analysis.
4.7. Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)
An RT-qPCR was performed to synthesize complementary (c)DNA from 1 µg of isolated RNA
using an RT kit (Thermo Fisher Scientific). Following the cDNA synthesis, let-7g and miR191
expressions were determined by a quantitative (q)PCR method using a TaqMan Gene Expression
Assay (Thermo Fisher Scientific) performed on a StepOnePlus Real-Time PCR System plus StepOne
software version 2.2.2 (Thermo Fisher Scientific). The relative gene expression level was calculated
from the ratio of the let-7g cycle threshold (CT) to the miR191 CT value.
4.8. Cell Culture and Transfection
Caco-2 and DLD-1 cells, obtained from American Type Culture Collection (ATCC, Manassas, VA,
USA), were grown in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin at 37 ◦C in 5% CO2. Before conducting the following experiments, cells were
transfected with either a miRNA negative control (100 nM) or let-7g mimic (100 nM) (Thermo Fisher
Scientific) using Lipofectamine (Thermo Fisher Scientific) in Opti-MEM (minimum essential medium;
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Thermo Fisher Scientific) for a least 16 h. Transfected cells were suspended using 0.05% trypsin
(Thermo Fisher Scientific) in phosphate-buffered saline (PBS) and used for the following experiments.
4.9. Cell Migration by a Wound-Healing Assay
Cells were seeded into culture inserts (ibidi, Munich, Germany), which were placed in 6-well
plates. Each well contained 5 × 104 cells in one insert supplied with DMEM at 37 ◦C in 5% CO2.
Following incubation overnight, the culture inserts were removed, and cells were then treated with or
without 25 ng/mL EGF in serum-free DMEM for 24 h. Cell migration was analyzed by measuring the
wound healing of Caco-2 and DLD-1 cells using microscopic imaging systems (Leica Camera, Wetzlar,
Germany) and Luma-controller (Etaluma, Carlsbad, CA, USA), respectively.
4.10. Cell Migration by a Biosensor Approach
An x’Celligence Biosensor System based on a real-time cell analyzer (RTCA) dual plate (DP)
instrument (Roche Diagnostics, Mannheim, Germany) was used to monitor and evaluate cell migration
according to the manufacturer’s instructions. The cell invasion and migration (CIM)-plate was
monitored once every 15 min. Data were collected and analyzed using RTCA v1.2 software
(Roche Diagnostics).
4.11. Transwell Cell Migration and Invasion Assays
Cells were suspended in 500 µL of serum-free DMEM and seeded into BD Falcon culture inserts
(BD Biosciences, San Jose, CA, USA) for the cell migration assay or into BD BioCoat™ Matrigel Invasion
Chambers (BD Biosciences) for the cell-invasion assay. Each insert or chamber contained 105 cells
and was placed in 24-well plates filled with 1 mL of DMEM with 10% FBS. After a 48-h incubation,
non-migrating cells that remained on the upper surface of the membrane in the insert of the chamber
were removed by scrubbing. Migrated cells on the reverse side of the membrane were fixed in 100%
methanol and then stained with 0.1% crystal violet. Cell migration and invasion were evaluated by
measuring the number of migrated cells using microscopic imaging (Leica Camera).
4.12. Western Blotting
Cells were harvested and lysed in radio-immunoprecipitation assay (RIPA) buffer with a protease
inhibitor, then total cell lysates were extracted to perform a Western blot analysis. Total cellular
proteins were first separated by 12.5% sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and then transferred onto polyvinyl difluoride (PVDF) membranes (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Membranes were blocked in 5% bovine serum albumin (BSA)
in 0.1% PBS/Tween-20 (PBST) for 1 h and then incubated with a primary antibody against p-Akt
(Cell Signaling Technology, Danvers, MA, USA), N-cadherin (Cell Signaling Technology), E-cadherin
(Cell Signaling Technology), vimentin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or GAPDH
(Santa Cruz Biotechnology) followed by incubation with a horseradish peroxidase (HRP)-conjugated
secondary antibody (GeneTex, Irvine, CA, USA). The signal of the target proteins was enhanced
by a chemiluminescent HRP substrate (EMD Millipore, Billerica, MA, USA) and then detected by
an electrochemiluminescence (ECL) detection system.
4.13. Calcium Imaging
Cells were seeded onto 20-mm coverslips in 6-well plates and grown in DMEM at 37 ◦C in 5% CO2.
After incubation overnight, cells were incubated with 1 µM Fluo-4-AM (Molecular Probes, Eugene,
OR, USA) in calcium-free buffer at 37 ◦C for 20 min. Following Fluo-4-AM staining, cells were treated
with 2 µM thapsigargin (TG) and then a 2 mM calcium solution to trigger calcium release by the
endoplasmic reticulum (ER) and extracellular calcium influx, respectively. Real-time intracellular Ca2+
signals were detected using an MT 20 illumination system (Olympus, Melville, NY, USA) mounted on
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an Olympus CellˆR IX81 fluorescence microscope with a UPLanApo 10× objective lens and estimated
based on the fluorescent intensities emitted upon excitation of consecutive 488-nm pulses of light at
a resolution of 1376 × 1038 pixels.
4.14. Animal Study
In this study, male Nu/Nu mice (5 weeks old with an average weight of 20.3 g; from National
Laboratory Animal Center, Taiwan) were subcutaneously injected with 1 × 107 number of Caco-2
cells. All the mice were injected intraperitoneally with the liposome containing microRNA negative
control or let-7g twice a week. And tumor volumes were calculated using the equation (L ×W2)/2,
where L and W are the larger and smaller tumor dimensions, respectively. After 17 days, the mice were
sacrificed, and all the tumors were excised and weighed. The protocol of animal experiments in this
study was reviewed and approved by the Institutional Animal Care and Use Committees (IACUCs)
of Kaohsiung Medical University (approval no: 106083) and Taipei Medical University (approval no:
LAC-2018-0346 and LAC-2019-0052).
4.15. Statistical Analysis
We performed all statistical and bioinformatics analysis using R software (http://www.r-project.
org/; http://cran.r-project.org/) and Bioconductor (http://www.bioconductor.org/). The statistical
difference in let-7g expression between tumor and normal tissues in CRC patients was determined
by the Wilcoxon test. A statistical analysis to compare other experimental results was performed
with Student’s t-test. A p-value of <0.05 was considered statistically significant and was denoted by *,
and a p-value of <0.01 was denoted by **.
5. Conclusions
In short, our results offer new insights into the clinical consequences of let-7g in CRC patients.
First, we confirmed the significant association between let-7g expression and the clinical status of CRC
patients from two independent cohorts. Second, we demonstrated a protective role of let-7g in CRC
cells via inhibition of cancer cell motility as well as attenuation of SOC signals. Third, our results
established the importance of let-7g treatment in determining subsequent cancer developmental events
in an in vivo model. Finally, our results identified let-7g as a rational diagnostic target aimed at
CRC metastasis.
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